Forty relapsing multiple sclerosis patients with 1-15 gadolinium (Gd)-enhancing lesions on screening brain magnetic resonance imaging
(MRI) and Expanded Disability Status Scale (EDSS) scores 0-6.5 were randomized to receive short-term induction therapy with mitoxantrone (three monthly 12
mg/m(2) infusions) followed by 12 months of daily glatiramer acetate (GA) therapy 20 mg/day subcutaneously for a total of 15 months (M-GA, n = 21) or daily GA
20 mg/day for 15 months (GA, n = 19). MRI scans were performed at months 6, 9, 12 and 15............
For the full abstract please go to MSRC: MS Research News : Drugs : Mitoxantrone and Copaxone Combination Therapy
For the full abstract please go to MSRC: MS Research News : Drugs : Mitoxantrone and Copaxone Combination Therapy
